Skip to main content

Table 2 Assay results for the determination of the studied drugs in their synthetic mixture and co-formulated tablets.

From: Development and validation of a repharsed phase- HPLC method for simultaneous determination of rosiglitazone and glimepiride in combined dosage forms and human plasma

Sample Concentration taken (μg/mL) Concentration found (μg/mL) % Found Reference method [14]
1- Synthetic mixture(a) ROS GLM ROS GLM ROS GLM ROS GLM
  0.25 0.125 0.249 0.127 99.60 101.60 99.10 100.27
  0.5 0.25 0.501 0.251 100.20 100.40 100.64 98.18
  1.0 0.5 1.013 0.506 101.30 101.20 98.00 99.73
  5.0 2.5 4.966 0.473 99.32 98.92   
  10.0 5.0 10.005 5.014 100.05 100.28   
  15.0 7.5 15.131 7.473 100.87 99.64   
  25.0 12.5 25.047 12.473 100.19 99.78   
X'      100.22 100.26 99.25 99.06
SD      0.68 0.92 1.33 1.08
%RSD      0.68 0.92   
±%Error      0.26 0.35   
t- test      1.58 1.80   
F- test      3.83 1.37   
2-AvandarylTM tablets(b) (4 mg ROS + 2 mg GLM/tablet) 0.25 0.125 0.253 0.123 101.20 98.40 98.10 101.56
  1.0 0.5 0.994 0.511 99.4 102.20 99.27 98.50
  5.0 2.5 5.038 2.543 100.76 101.72 100.71 100.40
  10.0 5.0 10.215 4.946 102.15 98.92   
X'      100.88 100.31 99.36 100.15
SD      1.14 1.93 1.31 1.54
%RSD      1.14 1.93   
±%Error      0.57 0.97   
t- test      1.65 0.12   
F- test      1.32 1.32   
  1. N.B.:
  2. (a) The values of tabulated t and F are (2.31) and (5.14) respectively at p = 0.05
  3. (b) The values of tabulated t and F are (2.57) and (9.550 respectively at p = 0.05